JP2017511387A - 脂質蓄積障害の治療のための方法および組成物 - Google Patents

脂質蓄積障害の治療のための方法および組成物 Download PDF

Info

Publication number
JP2017511387A
JP2017511387A JP2017506619A JP2017506619A JP2017511387A JP 2017511387 A JP2017511387 A JP 2017511387A JP 2017506619 A JP2017506619 A JP 2017506619A JP 2017506619 A JP2017506619 A JP 2017506619A JP 2017511387 A JP2017511387 A JP 2017511387A
Authority
JP
Japan
Prior art keywords
cells
npc1
vimentin
bryostatin
pkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017506619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511387A5 (enExample
Inventor
ヤニス エイ． イオアヌ
ヤニス エイ． イオアヌ
ローレンス オルトスティール
ローレンス オルトスティール
デビッド アール． クロックフォード
デビッド アール． クロックフォード
サタパナ コングサムット
サタパナ コングサムット
Original Assignee
ニューロトロープ バイオサイエンス インコーポレイテッド
ニューロトロープ バイオサイエンス インコーポレイテッド
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロトロープ バイオサイエンス インコーポレイテッド, ニューロトロープ バイオサイエンス インコーポレイテッド, アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical ニューロトロープ バイオサイエンス インコーポレイテッド
Publication of JP2017511387A publication Critical patent/JP2017511387A/ja
Publication of JP2017511387A5 publication Critical patent/JP2017511387A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
JP2017506619A 2014-04-18 2015-04-14 脂質蓄積障害の治療のための方法および組成物 Pending JP2017511387A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US61/981,473 2014-04-18
US201461987360P 2014-05-01 2014-05-01
US61/987,360 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (2)

Publication Number Publication Date
JP2017511387A true JP2017511387A (ja) 2017-04-20
JP2017511387A5 JP2017511387A5 (enExample) 2018-04-12

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506619A Pending JP2017511387A (ja) 2014-04-18 2015-04-14 脂質蓄積障害の治療のための方法および組成物

Country Status (9)

Country Link
US (3) US9724328B2 (enExample)
EP (1) EP3131543A4 (enExample)
JP (1) JP2017511387A (enExample)
KR (1) KR20170031653A (enExample)
CN (1) CN107072982A (enExample)
CA (1) CA2946115A1 (enExample)
IL (1) IL248494A0 (enExample)
MX (1) MX2016013680A (enExample)
WO (1) WO2015160851A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148975A1 (en) * 2014-03-27 2015-10-01 Alkon Daniel L Compositions and methods to treat niemann-pick disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
JP2003515601A (ja) 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
WO2004004641A2 (en) 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US10821079B2 (en) * 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148975A1 (en) * 2014-03-27 2015-10-01 Alkon Daniel L Compositions and methods to treat niemann-pick disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. Vol.8, No.8, e74169, JPN6018045398, 2013, pages 1 - 12, ISSN: 0004073837 *

Also Published As

Publication number Publication date
EP3131543A4 (en) 2017-12-20
US20150297559A1 (en) 2015-10-22
KR20170031653A (ko) 2017-03-21
US20190201377A1 (en) 2019-07-04
CN107072982A (zh) 2017-08-18
CA2946115A1 (en) 2015-10-22
US9724328B2 (en) 2017-08-08
WO2015160851A1 (en) 2015-10-22
EP3131543A1 (en) 2017-02-22
MX2016013680A (es) 2017-07-05
IL248494A0 (en) 2016-12-29
US20170172978A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
Toops et al. Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium
Jeon et al. Physiological and pathological roles of lipogenesis
Shekh-Ahmad et al. KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy
Renvoisé et al. Reep1 null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation
EP3065733B1 (fr) Composes et compositions comprenant de tels composes pour la prévention ou le traitement des dyslipidémies
Bruce et al. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice
US10124008B2 (en) Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations
JP2019509997A (ja) 神経血管形成疾患または障害の治療標的としてのｆｆａ１（ｇｐｒ４０）
Mizuno et al. The role of endocannabinoids in consolidation, retrieval, reconsolidation, and extinction of fear memory
US20190201377A1 (en) Methods and compositions for treatment of lipid storage disorders
US20170128479A1 (en) Treatment of peroxisome biogenesis disorder
WO2020163493A9 (en) Materials and methods for treating a neurodegenerative disease
AU2022283770B2 (en) Cyclic plasmenylethanolamines
Kalkman et al. Ceramides May play a central role in the pathogenesis of alzheimer’s disease: a review of evidence and horizons for discovery
US20050182020A1 (en) Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture
Gouna Lipid metabolism in remyelination: does a hidden dialogue exist between the central nervous system and the periphery?
US10251852B2 (en) Composition and methods for treatment of lung disorders characterized by cholesterol dysregulation
He et al. Allosteric activation of a cell-type-specific GPR120 inhibits amyloid pathology of Alzheimer’s disease
Zhou PMP22 Regulates Lipid Metabolism and Cholesterol Trafficking: The Implication for Hereditary Peripheral Neuropathies
Tan The full brain distribution of neutral sphingomyelinase 2 and its role in the striatum
Mokhtar The Role of Perilipin 5 (PLIN5) in Muscle Metabolism
Tan Organelle Trafficking in Health and Disease of the Retinal Pigment Epithelium
Taddeo Discovery of novel mechanisms in skeletal muscle and liver underlying the regulation of blood glucose homeostasis
Desai Sphingosine-1-Phosphate and Fingolimod (FTY720) Regulate ICl, swell In HL-1 Cardiac Myocytes via Intracellular Binding And Mitochondrial ROS Production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190710